These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6362815)

  • 1. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study.
    Stephens RL; Vaughn C; Lane M; Costanzi J; O'Bryan R; Balcerzak SP; Levin H; Frank J; Coltman CA
    Cancer; 1984 Feb; 53(3):406-10. PubMed ID: 6362815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate.
    Loening SA; Scott WW; deKernion J; Gibbons RP; Johnson DE; Pontes JE; Prout GR; Schmidt JD; Soloway MS; Chu TM; Gaeta JF; Slack NH; Murphy GP
    J Urol; 1981 Jun; 125(6):812-6. PubMed ID: 7017170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study.
    Drelichman A; Oldford J; Al-Sarraf M
    Am J Clin Oncol; 1985 Jun; 8(3):255-9. PubMed ID: 3840326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
    Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH
    J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study.
    Saxman S; Ansari R; Drasga R; Miller M; Wheeler B; McClean J; Einhorn L
    Cancer; 1992 Nov; 70(10):2488-92. PubMed ID: 1423178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
    Osborne CK; Blumenstein B; Crawford ED; Coltman CA; Smith AY; Lambuth BW; Chapman RA
    J Clin Oncol; 1990 Oct; 8(10):1675-82. PubMed ID: 2213104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
    Curry SL; Blessing JA; DiSaia PJ; Soper JT; Twiggs LB
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):357-62. PubMed ID: 2536911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
    Inoue K; Ogawa M; Inagaki J; Horikoshi N; Ikeda K; Nakada H; Usui N; Adachi K; Tada A; Yamazaki H
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1832-7. PubMed ID: 6433805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
    Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: a phase II study.
    Izbicki RM; Amer MH; Al-Sarraf M
    Cancer Treat Rep; 1979 Jun; 63(6):999-1001. PubMed ID: 380805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Pinedo HM; Bramwell VH; Mouridsen HT; Somers R; Vendrik CP; Santoro A; Buesa J; Wagener T; van Oosterom AT; van Unnik JA
    Cancer; 1984 May; 53(9):1825-32. PubMed ID: 6367947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
    Naik H; Lehr J; Akhtar A; Pienta K
    Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
    Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
    Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
    J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
    Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
    Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.